作者
Dirk De Ruysscher, Angela van Baardwijk, Jessie Steevens, Anita Botterweck, Geert Bosmans, Bart Reymen, Rinus Wanders, Jacques Borger, Anne-Marie C Dingemans, Gerben Bootsma, Cordula Pitz, Ragnar Lunde, Wiel Geraedts, Michel Oellers, Andre Dekker, Philippe Lambin
发表日期
2012/2/1
期刊
Radiotherapy and Oncology
卷号
102
期号
2
页码范围
228-233
出版商
Elsevier
简介
BACKGROUND
Individualised, isotoxic, accelerated radiotherapy (INDAR) allows the delivery of high biological radiation doses, but the long-term survival associated with this approach is unknown.
METHODS
Patients with stage III NSCLC in the Netherlands Cancer Registry/Limburg from January 1, 2002 to December 31, 2008 were included.
RESULTS
Patients (1002) with stage III NSCLC were diagnosed, of which 938 had T4 and/or N2–N3 disease. Patients treated with curative intent were staged with FDG-PET scans and a contrast-enhanced CT or an MRI of the brain. There were no shifts over time in the patient or tumour characteristics at diagnosis. The number of stage III NSCLC patients remained stable over time, but the proportion treated with palliative intent decreased from 47% in 2002 to 37% in 2008, and the percentage treated with chemo-radiation (RT) increased from 24.6% in 2002 to 47.8% in 2008 …
学术搜索中的文章
D De Ruysscher, A van Baardwijk, J Steevens… - Radiotherapy and Oncology, 2012